New HIV pill dose for kids shows promise in african study

NCT ID NCT05993767

Completed Disease control Sponsor: PENTA Foundation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new combination of three HIV drugs (dolutegravir, emtricitabine, and tenofovir alafenamide) in 53 children aged 28 days to 10 years in Africa. The goal was to find a dose that gives enough medicine in the blood and is safe. If it works, this could lead to a single, easy-to-take pill for children living with HIV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dolutegravir, emtricitabine, and tenofovir alafenamide (three anti-HIV drugs combined)
What this could lead to: If successful, this could lead to a simpler, child-friendly pill that helps control HIV in children across Africa.
What could go wrong: This is a small, early-phase study (53 children) focused on drug levels and safety, not on long-term cure. The new dose may not work for all children or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTION

Contacts and locations

Locations

Baylor College of Medicine Children's Foundation

Kampala, Uganda
Joint Research Centre

Kampala, Uganda
University of Zimbabwe Clinical Research Centre

Harare, Zimbabwe

More trials for these conditions

Other studies related to the condition(s) this trial covers.